골다공증 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 투여 경로별, 약물 유형별, 지역별 및 경쟁(2021-2031년)

The Global market for osteoporosis medications is expected to expand from USD 14.33 billion in 2025 to USD 18.38 billion by 2031, reflecting a compound annual growth rate of 4.24%. These pharmaceuticals are designed to halt bone degradation, increase bone mineral density, and lower fracture risks for patients with the condition. Growth in this sector is largely fueled by a rising elderly demographic, a higher global incidence of osteoporosis, ongoing diagnostic improvements, and growing education around bone health. A substantial opportunity for medical intervention exists, as the International Osteoporosis Foundation reported in October 2025 that as many as 80% of individuals experiencing osteoporotic fractures were neither diagnosed nor treated for the root cause.

Despite this potential, the market faces significant hurdles related to patients failing to adhere to prolonged treatment regimens, a problem worsened because osteoporosis typically presents no visible symptoms. Additionally, the high expenses linked to cutting-edge therapies and the risk of adverse side effects from specific drugs continue to impede wider market adoption.

Market Driver

The increasing worldwide incidence of osteoporosis and its associated fractures acts as a major catalyst for the growth of the osteoporosis drug industry. This widespread condition severely weakens bones, causing a surge in fractures across the globe and driving up the need for medical treatments. Data from the International Osteoporosis Foundation in October 2025 indicated that individuals over the age of 55 experience more than 37 million fragility fractures annually, highlighting the massive group of patients who need reliable pharmaceutical care to strengthen their bones and lower fracture risks. This high frequency guarantees an ongoing demand for both established and innovative medications.

At the same time, the expanding global elderly population plays a crucial role in accelerating market advancement, given that seniors face a naturally higher vulnerability to this bone disease. With life expectancies lengthening globally, the older demographic is growing, creating a broader segment of individuals at risk. The World Health Organization projected in February 2025 that the global population of those aged 60 and above will climb from 1.1 billion in 2023 to 1.4 billion by 2030, substantially widening the consumer base for these treatments. This demographic transformation heavily strains healthcare networks, with Capture the Fracture reporting in 2025 that fragility fractures placed a $400 billion financial burden on global healthcare systems.

Market Challenge

A major obstacle restricting the growth of the worldwide osteoporosis medication industry is the difficulty patients have in sticking to extended treatment plans. This issue is frequently worsened by the fact that osteoporosis lacks obvious symptoms, causing individuals to overlook the continuous need for care or fail to notice any immediate positive effects from their prescriptions. As a result, a large number of patients stop taking their medications too soon, which directly compromises the success of their prescribed medical treatments.

Inadequate commitment to therapy negatively impacts market expansion by lowering the overall usage and long-term need for these drugs. In August 2025, the International Osteoporosis Foundation noted that roughly 20 to 30 percent of patients fail to begin their recommended oral bisphosphonate regimens altogether, while roughly 40 percent of those who start will quit within the initial year. This high level of discontinuation results in poorer health outcomes and a heightened likelihood of fractures, ultimately capping the market's reach since the medications are not adequately employed to halt disease advancement or lower long-term fracture rates.

Market Trends

The worldwide market for osteoporosis treatments is being heavily shaped by a noticeable transition toward sophisticated biologics and anabolic drugs, highlighting a preference for stronger, more precise medical interventions. Unlike standard antiresorptive medications, these modern options utilize unique methods of action, such as actively encouraging the generation of new bone tissue. This medical progression equips doctors with superior choices for individuals suffering from severe osteoporosis or those unresponsive to older treatments, paving the way for enhanced health results and a lower likelihood of broken bones. Demonstrating the rising acceptance and commercial success of these innovative options, Amgen's financial report from February 2026 revealed that sales for its anabolic drug EVENITY (romosozumab-aqqg) surged by 34% throughout 2025.

At the same time, the rising presence of biosimilars is significantly altering the industry landscape by providing budget-friendly substitutes for prominent biologic drugs. This development improves patient accessibility, especially in areas with limited healthcare funding, while sparking fiercer rivalry among pharmaceutical companies. The introduction of biosimilars generally drives down costs, which helps broaden the pool of patients receiving care and promotes better compliance with lengthy treatment schedules by easing economic pressures. Highlighting this major increase in accessible alternatives for a popular osteoporosis biologic, the European Medicines Agency authorized 23 denosumab biosimilars in 2025.

Key Market Players

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Actavis PLC

Report Scope

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Route of Administration

• Oral
• Injectables
• Others

Osteoporosis Drugs Market, By Drug Type

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Selective Estrogen Receptor Modulators
• Others

Osteoporosis Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteoporosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Oral, Injectables, Others)
  • 5.2.2. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Drug Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Osteoporosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Drug Type
  • 6.3.2. Canada Osteoporosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Drug Type
  • 6.3.3. Mexico Osteoporosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Drug Type

7. Europe Osteoporosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Drug Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Osteoporosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Drug Type
  • 7.3.2. France Osteoporosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Drug Type
  • 7.3.3. United Kingdom Osteoporosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Drug Type
  • 7.3.4. Italy Osteoporosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Drug Type
  • 7.3.5. Spain Osteoporosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Drug Type

8. Asia Pacific Osteoporosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Drug Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Osteoporosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Drug Type
  • 8.3.2. India Osteoporosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Drug Type
  • 8.3.3. Japan Osteoporosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Drug Type
  • 8.3.4. South Korea Osteoporosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Drug Type
  • 8.3.5. Australia Osteoporosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Osteoporosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Drug Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Osteoporosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Drug Type
  • 9.3.2. UAE Osteoporosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Drug Type
  • 9.3.3. South Africa Osteoporosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Drug Type

10. South America Osteoporosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Drug Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Osteoporosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Drug Type
  • 10.3.2. Colombia Osteoporosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Drug Type
  • 10.3.3. Argentina Osteoporosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Osteoporosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Teva Pharmaceutical Industries Ltd.
• 15.5. GlaxoSmithKline plc.
• 15.6. Novartis International AG
• 15.7. Merck & Co. Inc.
• 15.8. Amgen Inc.
• 15.9. Radius Health Inc.
• 15.10. Actavis PLC

16. Strategic Recommendations

17. About Us & Disclaimer